Fountain presents hormone care through kits and recurring purchase periods. This makes the offer easy to recognize as a service to buy, but it can leave the reason for each medicine less visible. For progesterone, the question is what clinical purpose the proposed preparation serves, not simply whether it appears within a hormone kit.

We reviewed Fountain’s women’s hormone page and published terms on September 29, 2026. The offer names progesterone but does not confirm a particular oral capsule. The terms explain a subscription relationship and a separate medical-provider relationship. Neither relationship alone tells a reader how surgical history, estrogen exposure or a new symptom would affect the clinical plan.

Editorial illustration: two consultation chairs and a notebook on a side table.
Fountain menopause review: a treatment kit is not an explanation of every medicine — bring the unanswered questions into the appropriate professional conversation.

A kit name should lead to a medicine-by-medicine explanation

The hormone-therapy page establishes an actual menopause care offering and names progesterone within its treatment discussion. It does not supply a complete label for an oral progesterone product. A kit is a commercial grouping, so its contents should not be assumed to have one shared clinical purpose. The systemic estrogen guide explains why protection of the uterine lining can be a different objective from symptom relief. Fountain’s public description does not demonstrate which objective would apply to a reader or establish that every hormone mentioned is part of every prescribed plan.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
A kit name should lead to a medicine-by-medicine explanation — keep the exact product identity and its complete label together.

The medical group and the platform have different roles

Fountain’s terms, dated April 3, 2024, describe medical services through independent medical groups and leave prescribing to clinical judgment. They also discuss the ability to use a chosen pharmacy with a valid prescription. That does not establish that an outside pharmacy’s charges are included in Fountain’s kit price or that a specific prescription will be issued. The practical question is who explains the reason for each medicine and who remains responsible for reassessment. Lifeforce’s review examines another program with several service elements, useful for comparing responsibilities without assuming that a platform subscription and a clinical relationship are the same thing. A pharmacy can explain the dispensed product and its label, while the prescriber explains why it belongs in the treatment plan. The terms do not show a completed handoff between those roles for a particular patient, so both responsibilities should remain visible in the comparison.

The payment periods are four, twelve and forty-eight weeks

Fountain’s price display shows Starter at $199 per four weeks, with $199 charged every four weeks. Standard is displayed at $167 per four weeks but billed as $499 every twelve weeks. Pro displays $150 per four weeks with a $1,799 payment every forty-eight weeks. The displayed equivalents should not replace the actual commitment amounts, and these are not calendar-month or calendar-year periods. None proves a personal quantity of progesterone or the duration of a particular clinical decision. Comparing Alpha Hormones requires retaining its different monthly and annual units rather than treating all recurring offers as identical subscriptions.

Editorial illustration: a calculator, an open purchase ledger and an unbranded container.
The payment periods are four, twelve and forty-eight weeks — compare what the payment covers, when it renews and which charges remain separate.

Automatic renewal cannot stand in for clinical review

Under Fountain’s subscription terms, a subscription renews automatically unless the customer contacts Fountain to cancel before the current period ends; account closure occurs at the end of that period. Personal refund outcomes and the selected agreement still require confirmation. Those published conditions describe the purchase relationship, not evidence that a clinician has reconsidered the original treatment goal. ACOG’s patient guidance describes revisiting symptoms and the balance of benefits and risks over time. A plan’s continued billing therefore cannot answer whether a medicine’s purpose remains appropriate, who checks changes in health history, or when another clinical conversation should occur.

The history behind a hysterectomy should remain visible

The BMS guidance for induced menopause in endometriosis discusses treatment after hysterectomy differently from a simple universal estrogen-only rule. Residual disease and individual risk matter, and the guidance acknowledges that high-quality evidence is limited. This does not establish how Fountain assesses surgical history, or give a reader a reason to alter treatment independently. It explains why the hysterectomy questions guide asks for a professional interpretation of the relevant history. The kit page does not contain a patient’s operative findings or show that a medical group has reviewed them. Those missing details cannot be supplied by a subscription tier.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
The history behind a hysterectomy should remain visible — keep the exact product identity and its complete label together.

A local estrogen discussion is a different comparison

The 2020 NAMS consensus abstract says a progestogen is not indicated with low-dose vaginal estrogen, while identifying the absence of endometrial-safety trials beyond one year. That is qualified guidance about a defined treatment context, not a blanket rule for every product used vaginally. Fountain’s general hormone page cannot classify an unidentified existing medicine for the reader. The local vaginal estrogen guide separates this question from systemic estrogen. Before a kit is interpreted as a complete plan, the clinician needs to explain the identity and intended exposure of the medicines actually involved, rather than relying on the broad term hormone therapy.

Convenience claims do not define an urgent-care pathway

Fountain advertises shipping and support on its service page, but those claims do not guarantee clinical assessment of a new symptom within a particular interval. Its terms explicitly direct emergencies to emergency services rather than the platform. Separately, NHS guidance says postmenopausal bleeding needs checking even when brief or slight; this review cannot diagnose its cause. The unexpected bleeding guide explains why routine refill or membership questions should not replace professional evaluation. Fountain’s offer is documented, but an individual still needs clarity about the medicine, its purpose, the responsible medical group and the appropriate route for a change in circumstances.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. Fountain: Hormone therapy for womenProvider clinical service and kit; full four-, twelve- and forty-eight-week billing periods retained, exact capsule unconfirmed · Checked 2026-09-29
  2. Fountain: Terms and conditionsProvider terms dated April 3, 2024; medical-group, prescription and pharmacy-choice clauses, not individual coverage or refund confirmation · Checked 2026-09-29
  3. ACOG: Hormone Therapy for MenopauseUS professional patient guidance, last updated October 2021 and reviewed February 2024; treatment categories and reassessment, not individual prescribing or a provider protocol · Checked 2026-09-29
  4. British Menopause Society: Induced menopause in women with endometriosis, February 2026UK professional clinical tool, February 2026; post-hysterectomy exceptions depend on residual disease and individual risks, with limited high-quality evidence and case-by-case decisions · Checked 2026-09-29
  5. NAMS: The 2020 genitourinary syndrome of menopause position statement — abstractPublished professional consensus abstract only; low-dose vaginal estrogen distinction retains absent endometrial-safety clinical trials beyond one year, not a complete-paper or individualized assessment · Checked 2026-09-29
  6. NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29
Read our editorial method →